Quick Chats - The Importance of Client Experience
Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences, shares how caring for sponsors' programs and studies is what sets Altasciences apart from other CDMO's and CRO's.
...working with Altasciences has been excellent, from both a bioanalytical, and a bioavailability study perspective. We are really impressed with their planning and execution abilities – I would not consider another provider for future work.
Read the blog
Genome editing (or gene editing) is a group of technologies that allow scientists to change an organism's DNA, by removing, altering, or adding to specific locations in the genome.
Bring your talents and forward-thinking approach to Altasciences and help us develop medicines for those who need them, faster. We have a number of opportunities for you to explore.
Press Release
Altasciences is expanding its current clinical operations in Montreal and Kansas City with the addition of a clinical CRO on the U.S.A.'s West Coast. Click below to read more about the acquisition of WCCT Global.
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
From formulation development, Phase I through commercial manufacturing, and ICH stability testing
As part of our full service offering or as standalone solutions
Comprehensive CRO services to support clinical and preclinical studies
Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences, shares how caring for sponsors' programs and studies is what sets Altasciences apart from other CDMO's and CRO's.
Working as a flexible, attentive extension of your team, we offer comprehensive drug development services to move your molecule forward.
Join our list of 10,000+ VIP members and have access to our exclusive content.
You can unsubscribe at any time. For more details, please review our privacy policy.
2019 © Altasciences. All Rights Reserved.